Patent of OBI-858 “Clostridium Botulinum toxin Type A composition, formulation and use thereof” was granted by the Taiwan Intellectual Property Office

1. Date of occurrence of the event: July 27, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. Reciprocal shareholding ratios: Not applicable 5. Cause of occurrence: OBI Pharma Inc. was informed by the patent agency that patent for OBI-858 “Clostridium botulinum toxin […]

This article is password protected.

To view the content, please enter your password in the field below